CAR T-Cell Therapy Starts to Enter MCL Space – OncLive
OncLive |
CAR T-Cell Therapy Starts to Enter MCL Space
OncLive What are the main challenges that exist for this patient population? Once ibrutinib stops working or if patients come off ibrutinib, we know that the disease may progress rapidly. These patients have very little time to be referred and enrolled onto … |
